{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:27Z","timestamp":1790983167372,"version":"4.1.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":223,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Intravenous immunoglobulin (IVIG) therapy can occasionally induce unexpected inflammatory complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A case report and literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We report a patient with hypogammaglobulinemia and systemic autoimmunity who developed reproducible unilateral anterior uveitis following IVIG administration across multiple formulations. Discontinuation of IVIG resolved the ocular inflammation but caused underlying disease exacerbation. Transition to facilitated subcutaneous immunoglobulin (SCIG) achieved stable serum IgG levels and maintained complete ocular and systemic remission over a four-year follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates peak-driven immune activation as a plausible mechanism for IVIG-induced uveitis and highlights SCIG as a safe, effective therapeutic alternative that bypasses rapid peak IgG dynamics while preserving immune protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/immadv\/ltag018","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:49:48Z","timestamp":1786189788000},"source":"Crossref","is-referenced-by-count":1,"title":["IVIG-associated anterior uveitis resolving after switch to subcutaneous immunoglobulin"],"prefix":"10.1093","volume":"6","author":[{"given":"Vered","family":"Schichter Konfino","sequence":"first","affiliation":[{"name":"Allergy and Clinical Immunology Unit, Hillel Yaffe Medical Center , Hadera ,","place":["Israel"]},{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3188-2707","authenticated-orcid":false,"given":"Oded","family":"Shamriz","sequence":"additional","affiliation":[{"name":"The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada (IMRIC), Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem ,","place":["Israel"]},{"name":"Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026082613164105300_ltag018-B1","first-page":"83","article-title":"Adverse reactions to intravenous immunoglobulin therapy: a review of 100 cases","volume":"17","author":"Kessary-Shoham","year":"1999","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026082613164105300_ltag018-B2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"key":"2026082613164105300_ltag018-B3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ajoc.2017.03.005","article-title":"Bilateral uveitis following intravenous immunoglobulin administration","volume":"19","author":"Kocak","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2026082613164105300_ltag018-B4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/0140-6736(92)90385-G","article-title":"Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy","volume":"339","author":"Ayliffe","year":"1992","journal-title":"Lancet"},{"key":"2026082613164105300_ltag018-B5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000187996","article-title":"Retinal vasculitis and uveitis\u2013an adverse reaction to intravenous immunoglobulins?","volume":"67","author":"V\u00f6gele","year":"1994","journal-title":"Nephron"},{"key":"2026082613164105300_ltag018-B6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/ijo.IJO_816_20","article-title":"Drug-induced uveitis: a review","volume":"65","author":"Agarwal","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"2026082613164105300_ltag018-B7","first-page":"16035","article-title":"Uveitis: etiology and clinical spectrum","volume":"2","author":"Rosenbaum","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026082613164105300_ltag018-B8","first-page":"471","article-title":"IVIG therapy in autoimmune diseases: mechanisms of action","volume":"4","author":"Shoenfeld","year":"2005","journal-title":"Autoimmun Rev"},{"key":"2026082613164105300_ltag018-B9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/0004563221989737","article-title":"Calculated globulin as a screening tool for hypogammaglobulinaemia or paraproteins in hospitalized patients","volume":"58","author":"Hoo","year":"2021","journal-title":"Ann Clin Biochem"},{"key":"2026082613164105300_ltag018-B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00415","article-title":"Comparison of diagnostic criteria for common variable immunodeficiency disorder","volume":"5","author":"Ameratunga","year":"2014","journal-title":"Front Immunol"},{"key":"2026082613164105300_ltag018-B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltag018\/70611259\/ltag018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag018\/70611259\/ltag018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag018\/70611259\/ltag018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:16:49Z","timestamp":1787764609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltag018\/8758969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltag018","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,12,31]]},"article-number":"ltag018"}}